α-Difluoromethylornithine inhibits bone resorption in vitro without decreasing β-glucuronidase release

P. H. Stern*, R. C. Lucas, J. Seidenfeld

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Our previous studies suggested that the ornithine decarboxylase inhibitor α-difluoromethylornithine (DFMO) inhibits bone resorption by mechanisms that are independent of polyamine depletion. To determine whether DFMO prevents calcitriol-stimulated bone resorption by acting at a step before or after osteoclast activation, we compared the effects of DFMO on release of calcium and β-glucuronidase from cultured neonatal mouse calvaria. DFMO, at concentrations of 7.5-20 mM, inhibited release of calcium from calcitriol-stimulated calvaria but failed to inhibit the calcitriol-stimulated increase in β-glucuronidase secretion. In contrast, ornithine, putrescine, spermidine, and spermine, at concentrations with effects on resorption comparable to those of DFMO, inhibited the effects of calcitriol on both calcium and β-glucuronidase release. NaF (0.2 mM), like DFMO, inhibited calcitriol-stimulated calcium release without affecting medium β-glucuronidase activity, whereas elevated phosphate (3 mM) inhibited both activities. The results suggest that DFMO, over the concentration range studied, inhibits calcium release by marking the matrix resistant to resorption rather than by acting at a cellular locus.

Original languageEnglish (US)
Pages (from-to)557-562
Number of pages6
JournalMolecular Pharmacology
Volume39
Issue number4
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'α-Difluoromethylornithine inhibits bone resorption in vitro without decreasing β-glucuronidase release'. Together they form a unique fingerprint.

  • Cite this